Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07533955
PHASE1

A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis

Sponsor: Jade Biosciences, Inc.

View on ClinicalTrials.gov

Summary

This is a Phase 1, first in human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of JADE201 compared to placebo in participants with Rheumatoid Arthritis

Official title: A Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JADE201 Administered Subcutaneously in Participants With Rheumatoid Arthritis

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

36

Start Date

2026-05-19

Completion Date

2028-10

Last Updated

2026-10-23

Healthy Volunteers

No

Interventions

DRUG

JADE201

JADE201 is supplied as sterile solution to be administered by SC injection.

DRUG

Placebo

Placebo solution to be administered at a matching volume by SC injection.

Locations (8)

Jade Clinical Site

Sofia, Bulgaria

Jade Clinical Site

Tbilisi, Georgia

Jade Clinical Site

Berlin, Germany

Jade Clinical Site

Chisinau, Moldova, Moldova

Jade Clinical Site

Bucharest, Romania

Jade Clinical Site

Cluj-Napoca, Romania

Jade Clinical Site

Ivano-Frankivsk, Ukraine, Ukraine

Jade Clinical Site

Kyiv, Ukraine, Ukraine